CD34 PAT3B6AT Antibody
Description
Hematopoietic Stem Cell Research
CD34 antibodies enable isolation and characterization of HSCs for transplantation and in vitro differentiation studies .
-
Positive selection: Enrichment of CD34+ cells from bone marrow or peripheral blood for autografts .
-
Lineage tracing: Distinguishing primitive HSCs (CD34+CD38−) from lineage-committed progenitors .
Leukemia Diagnostics and Therapy
CD34+ blasts are prevalent in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) . Antibodies like QBEnd10 and Immu133 aid in:
-
Blast detection: Flow cytometry-based identification of CD34+ leukemic cells .
-
Targeted therapies: CD34/CD3 bispecific T-cell engagers (BTEs) deplete CD34+ AML blasts while sparing healthy HSCs .
Tumor Microenvironment Studies
CD34+ stromal cells in solid tumors (e.g., GISTs) influence angiogenesis and metastasis . Antibodies like MSVA-034R validate stromal CD34 expression in histopathology .
Antibody Specificity and Validation
-
Western blotting: Clone 3D5 (from peptide immunization) detects a 110 kDa band in umbilical cord blood lysates .
-
Flow cytometry: MAB72274 distinguishes CD34+ KG-1 cells from CD34− K562 cells .
-
Cross-reactivity: Polyclonal antibodies (e.g., AF5149) show broader reactivity (human, mouse, rat) .
Clinical and Preclinical Insights
-
AML treatment: CD34-specific BTEs reduce leukemic cells in xenograft models, preserving HSC function .
-
HSC purification: CD34 antibodies improve engraftment rates in bone marrow transplants .
Limitations and Future Directions
-
Epitope variability: Glycosylation patterns affect antibody binding, necessitating epitope-classified reagents .
-
Off-target effects: CD34+ HSC depletion in BTE therapies requires precise dosing to avoid myelosuppression .
-
Emerging uses: CD34 antibodies may aid in mesenchymal stem cell identification and angiogenesis quantification .
Product Specs
CD34 molecule, Hematopoietic progenitor cell antigen CD34, CD34 Antigen, CD34.
CD34 antibody was purified from mouse ascitic fluids by protein-A affinity chromatography.
PAT3B6AT.
Anti-human CD34 mAb, is derived from hybridization of mouse F0 myeloma cells with spleen cells from BALB/c mice immunized with recombinant human CD34 amino acids 32-290 purified from E. coli.
Mouse IgG1 heavy chain and κ light chain.
Product Science Overview
Clone PAT3B6AT is a specific monoclonal antibody that targets the CD34 antigen. This clone is derived from mouse and is specifically designed to bind to human CD34. The monoclonal antibody is produced by immunizing mice with human CD34+ cells, followed by hybridoma technology to generate a stable cell line that produces the antibody.
The Mouse Anti-Human CD34 Clone PAT3B6AT is widely used in various scientific applications, including:
- Flow Cytometry: This antibody is commonly used in flow cytometry to identify and isolate CD34+ cells from a mixed cell population. It helps in the analysis of hematopoietic stem cells and progenitor cells.
- Immunohistochemistry: It is used to stain tissue sections to visualize the distribution and localization of CD34+ cells within the tissue.
- Western Blot: The antibody can be used to detect CD34 protein levels in cell lysates or tissue extracts.
- Immunocytochemistry: It is employed to stain cultured cells to study the expression and localization of CD34.
The CD34 antigen is a critical marker for identifying hematopoietic stem and progenitor cells. It is extensively used in stem cell research, particularly in the isolation and characterization of stem cells for therapeutic purposes. The ability to identify and isolate CD34+ cells is essential for bone marrow transplantation, regenerative medicine, and cancer research.
